Revvity Gene Delivery, where SIRION Biotech’s expertise lives on, supports your cell and gene therapy development process, offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production.

Whether you need small scale viral production or full scale viral vector optimization and manufacture, Revvity Gene Delivery has you covered, supporting you through every phase of your cell and gene therapy development.

The Revvity gene delivery advantage

With clients in Cancer Research, Neurosciences, Regenerative Medicines, Gene Therapy, CAR-T Cell Development & Vaccine Development, we understand the technical challenges of viral vector engineering and manufacturing, no matter what your application.

More than 15 years of viral vector development and production experience
- Flexible production scales up to 50 liters
- Extensive range of customizable QC options
- CDMO network for smooth transfer of processes to GMP manufacturing
- Comprehensive consultation and project management by viral vector experts

Research and discovery:
- Therapeutic payload identification (e.g. microRNA sequences)
- Novel AAV capsid engineering (e.g.AAV Evolution)
- Nanobody targeting

Viral vector development:
- Optimized Viral Vector Backbones
- Therapeutic payload cassette optimization
- Lentivirus surface modification technology

Preclinical manufacture:
- Upstream and downstream process development (non-GMP)
- Up to 50L AAV manufacturing capacity
- PoC and biodistribution studies of lead candidate batches with a CRO network

Revvity offer LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cell types like CAR-T cells and CD34+ hematopoietic stem cells. LentiBOOST® is currently included in more than 20 Phase III and I/II clinical trials.